CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
Rhea-AI Summary
CervoMed (NASDAQ: CRVO) received a USPTO notice of allowance for a new U.S. patent covering use of its drug candidate neflamapimod to treat dementia with Lewy bodies (DLB) in patients without substantial Alzheimer’s-like tau pathology, or “pure DLB”.
The patent, based on biomarker-defined patients using plasma pTau or brain imaging, is expected to provide intellectual property protection into 2042, supporting CervoMed’s pure DLB treatment strategy. There are currently no approved DLB treatments in the U.S. or EU.
Positive
- USPTO notice of allowance for new U.S. patent on neflamapimod use in pure DLB
- Patent expected to provide intellectual property protection for neflamapimod DLB use into 2042
- Protection focused on biomarker-defined DLB patients without substantial tau pathology
- Patent supports company strategy targeting treatment of patients with pure dementia with Lewy bodies
Negative
- No approved treatments for dementia with Lewy bodies in U.S. or European Union
News Market Reaction – CRVO
In the Jun 18 session, CRVO gained 11.29%, reflecting a significant positive market reaction. Argus tracked a peak move of +93.8% during that session. Argus tracked a trough of -3.0% from its starting point during tracking. Our momentum scanner triggered 59 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 7.2x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 12 | Conference participation | Neutral | -0.4% | Announcement of participation in H.C. Wainwright neuro perspectives summit. |
| Jun 10 | Financing & strategy | Negative | -22.1% | Private placement financing to fund neflamapimod Phase 3 and partnering plans. |
| May 18 | Earnings & update | Neutral | -11.6% | Q1 2026 results, cash position, loss, and neflamapimod program progress. |
| Apr 22 | Clinical data update | Positive | +0.8% | Positive MRI and connectivity data from RewinD-LB Phase 2b in DLB. |
| Apr 07 | Clinical program update | Positive | -3.5% | Neflamapimod clinical update and biomarker discussion at LBDA meeting. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent CRVO news, including financing and clinical/earnings updates, often coincided with downside moves, suggesting a tendency for the stock to trade weakly around announcements.
Key Terms
dementia with lewy bodies medical
pure dlb medical
ptau medical
patent term extension regulatory
united states patent and trademark office regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) related to a new patent protecting the Company’s use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies (DLB) in patients with no substantial Alzheimer’s disease-like tau pathology, also known as “pure DLB”.
The patent will cover the treatment of DLB without substantial tau pathology, which can be characterized by plasma levels of pTau or brain imaging, and is expected to provide intellectual property protection into 2042 and potentially longer with patent term extension. The patent is designed to protect the Company’s strategy targeting the treatment of patients with pure DLB. Currently, there are no approved treatments for DLB in the United States or European Union.
About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without Alzheimer’s disease (AD) co-pathology, and the Company announced alignment with the US Food and Drug Administration (FDA) on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA), a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.
Forward-Looking Statements
This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the Company’s need to acquire sufficient funding, including funding for any Phase 3 trial in patients with DLB; the Company’s plan to focus on strategic partnering to advance neflamapimod into Phase 3 for DLB and the timing of entering into any such partnership, if at all; the intellectual property protection afforded by the Company’s patent portfolio or any patent therein; the therapeutic potential of neflamapimod in DLB, nfvPPA, amyotrophic lateral sclerosis, or any other indication, including the degree of sustainability of any therapeutic effects; the anticipated timing and achievement of clinical and development milestones, including the Company’s initiation of any Phase 3 trial in patients with DLB; the anticipated data readouts from the Company’s Phase 2a trial in nfvPPA and the anticipated dosing of the first patient with neflamapimod in the EXPERTS-ALS trial; any other expected or implied benefits or results, including the extent (if any) to which neflamapimod may demonstrate efficacy or other clinical or biomarker improvements in patients; and expectations with respect to neflamapimod, including the timing of any regulatory submissions and potential approvals thereof, if any, in DLB or any other indication. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “aims,” “seeks,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential,” “target,” “project,” “contemplate,” “predict,” “forecast,” “continue,” or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company’s available cash resources, the availability of additional funds on acceptable terms or at all, and the Company’s ability to continue as a going concern; the results of the Company’s clinical trials; the Company’s ability to successfully enter into a partnership to advance neflamapimod into Phase 3 for DLB in a timely manner, on acceptable terms, or at all; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA or other regulators; the Company’s ability to maintain the intellectual property protection afforded by the Company’s patent portfolio; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the US Securities and Exchange Commission (SEC) on March 13, 2026, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.
Contacts
Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431
Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902
